Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The Meningitis Vaccine Project.

F Marc LaForce1, Kader Konde, Simonetta Viviani

  • 1The Meningitis Vaccine Project, PATH, 13 Chemin du Levant, 01210 Ferney-Voltaire, France. fmlaforce@path.org

Vaccine
|May 25, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Haploidentical allogeneic hematopoietic stem cell transplantation in relapsed/refractory Hodgkin lymphoma in the era of novel agents: a single-center experience.

Leukemia & lymphoma·2026
Same author

Advanced stage classical Hodgkin lymphoma patients with a positive interim-PET (PET-2) Deauville score 5 after 2 ABVD cycles: a pooled analysis of three multicenter trials.

Blood cancer journal·2025
Same author

Erratum: Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607 Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025
Same author

Immunogenicity and safety of a meningococcal a conjugate vaccine administered with routine EPI vaccines in African infants and toddlers.

Vaccine·2025
Same author

Development of MenFive®, an affordable pentavalent meningococcal conjugate vaccine (ACYWX) for Africa and beyond.

Human vaccines & immunotherapeutics·2025
Same author

WHO defeating meningitis symposium, 3rd international symposium on Streptococcus agalactiae disease (ISSAD) in Rio de Janeiro, Brazil: State-of-the-art overview of S. agalactiae meningitis.

Vaccine·2025
Same journal

Immunogenicity and safety of a SARS-CoV-2 recombinant vaccine S-268024 booster vaccination versus NVX-CoV2373: Interim results from a phase 3, multicenter, randomized, observer-blind, active-controlled study.

Vaccine·2026
Same journal

Safety and immunogenicity of a reduced, homologous booster dose of the BNT162b2 mRNA COVID-19 vaccine: a single blind, randomized, non-inferiority follow-up trial.

Vaccine·2026
Same journal

Vaccination policies for healthcare personnel in Europe, 2026.

Vaccine·2026
Same journal

A historical overview of the anti-vaccine movement and its public health implications.

Vaccine·2026
Same journal

Vaccine strategies and development before and during the 1968 H3N2 influenza pandemic.

Vaccine·2026
Same journal

Influence of correlated vaccination behaviors on estimates of COVID-19 vaccine effectiveness in older adults - VISION network, October 2023 - March 2024.

Vaccine·2026
See all related articles

A new meningococcal A (Men A) conjugate vaccine offers a safe and effective way to control epidemic meningitis in Africa. This vaccine, developed through a global partnership, aims to eliminate the disease by inducing herd immunity.

Area of Science:

  • Public Health
  • Vaccinology
  • Epidemiology

Background:

  • Epidemic meningococcal meningitis poses a significant public health challenge in sub-Saharan Africa.
  • Current polysaccharide vaccines have limitations in infants and do not induce herd immunity.
  • Conjugate vaccines offer improved efficacy in infants and reduce disease transmission.

Purpose of the Study:

  • To develop and introduce an affordable meningococcal A (Men A) conjugate vaccine for epidemic control in Africa.
  • To eliminate meningococcal epidemics through widespread use of conjugate vaccines.
  • To establish a sustainable model for vaccine development in the developing world.

Main Methods:

  • Development of an affordable Men A conjugate vaccine through international partnership and technology transfer.

Related Experiment Videos

  • Phase 1 safety and immunogenicity study in India.
  • Phase 2 studies initiated in Africa, with a planned large demonstration study.

    • Main Results:

    • The Men A conjugate vaccine demonstrated safety and immunogenicity in Phase 1 trials.
    • Phase 2 studies are underway in Africa.
    • A comprehensive vaccine introduction plan has been developed.

    Conclusions:

    • The Meningitis Vaccine Project (MVP) is developing a crucial Men A conjugate vaccine for Africa.
    • The MVP model demonstrates the success of public-private partnerships in addressing global health needs.
    • The vaccine's introduction strategy includes routine immunization and mass vaccination to achieve herd immunity.